Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax: A Real-World Experience in Pharmacovigilance

Mary Burke, David A Sallman, Ariel Denson, Rebecca Jean Nelson, Onyee Chan, Alison R. Walker, Eric Padron, Zhuoer Xie, Rami S. Komrokji, Jeffrey Lancet, Andrew T. Kuykendall, Katherine Tobon, Akriti Gupta Jain, Chen Wang, Najla H Al Ali

Blood (2023) 142 (Supplement 1): 2899.

https://doi.org/10.1182/blood-2023-187206

Published: 2023

Journal Articles

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Andrew T. Kuykendall, Kristen Marie Pettit, Abhay Singh, Tania Jain, David A Sallman, Qianxing Mo, Quan Lovette, Ling Zhang, Onyee Chan, Alison R. Walker, Zhuoer Xie, Jeffrey Lancet, Maria Balasis, Seongseok Yun, Eric Padron, Rami S. Komrokji

Blood (2023) 142 (Supplement 1): 73.

https://doi.org/10.1182/blood-2023-182879

Published: 2023

Journal Articles

Improved Overall Survival Among Luspatercept Responders and Predictors of Response

Blood (2023) 142 (Supplement 1): 1871.

https://doi.org/10.1182/blood-2023-186279

Published: 2023

Journal Articles

Outcomes in Patients with Acute Myeloid Leukemia Treated with CLAG (cladribine, cytarabine, filgrastim) and/or Mitoxantrone with Venetoclax

Onyee Chan, Luis E. Aguirre, Mary Burke, Najla H Al Ali, Zhuoer Xie, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Jeffrey Lancet, Rami S. Komrokji, David A Sallman

Blood (2023) 142 (Supplement 1): 5935.

https://doi.org/10.1182/blood-2023-173637

Published: 2023

Journal Articles

Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) Is Associated with Better Overall Survival

Rami S. Komrokji, Muhammad Ammad-ud-din, Najla H Al Ali, Zhuoer Xie, Onyee Chan, Andrew T. Kuykendall, Seongseok Yun, Alison R. Walker, Jeffrey Lancet, Eric Padron, David A Sallman

Blood (2023) 142 (Supplement 1): 1867.

https://doi.org/10.1182/blood-2023-186843

Published: 2023

Journal Articles

Aplastic Anemia: Insight from a Single Center Experience

Parth C. Patel, Najla H Al Ali, Onyee Chan, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Kendra Sweet, Alison R. Walker, Jeffrey Lancet, David A Sallman, Michael V. Jaglal, Rami S. Komrokji

Blood (2023) 142 (Supplement 1): 5649.

https://doi.org/10.1182/blood-2023-178952

Published: 2023

Journal Articles

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Blood (2022) 140 (Supplement 1): 3419–3421.

https://doi.org/10.1182/blood-2022-165802

Published: 2022

Journal Articles

Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75

Kieran D Sahasrabudhe, Melanie T Rebechi, Ying Huang, Greg K. Behbehani, Bhavana Bhatnagar, James S. Blachly, Bradley W Blaser, Uma Borate, Ramiro Garzon, Tamanna Haque, Karilyn Larkin, Meixiao Long, Alice S. Mims, Ayman Saad, Sumithira Vasu, Alison R. Walker, Sarah A Wall

Blood (2021) 138 (Supplement 1): 4125.

https://doi.org/10.1182/blood-2021-148676

Published: 2021

Journal Articles

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Universally Alloreactive Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Sumithira Vasu, Nidhi Sharma, Alison R. Walker, Sarah A Wall, James S. Blachly, Greg K. Behbehani, Hannah Choe, Aarohi Thakkar, Robin Nakkula, Ella Troy, Nicole Szuminski, Marcos J.G. de Lima, Lynn O'Donnell, Dean Anthony Lee

Blood (2021) 138 (Supplement 1): 1732.

https://doi.org/10.1182/blood-2021-150750

Published: 2021

Journal Articles

Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy

Bethany Lockwood, MD, Areej El-Jawahri, MD, Alison R. Walker, MD, Deborah Russell, FNP-BC,ACHPN, Jillian Gustin, MD, Sarah Ehrman, MD, Seuli Bose-Brill, MD, Maryam Lustberg, MD, Bhavana Bhatnagar, DO

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-140589

Published: 2020

Journal Articles

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Bhavana Bhatnagar, DO, Shelley Orwick, BS, Nyla A. Heerema, PhD, Alison R. Walker, MD, Alice S. Mims, MD, James S. Blachly, MD, Karilyn Larkin, MD, Nicole Grieselhuber, MD PhD, Gregory K. Behbehani, MD PhD, Apollinaire Ngankeu, Charles Thomas Gregory, BS, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1329.

https://doi.org/10.1182/blood-2019-130856

Published: 2019

Journal Articles

Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial

Blood (2019) 134 (Supplement_1): 175.

https://doi.org/10.1182/blood-2019-130201

Published: 2019

Journal Articles

Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Blood (2018) 132 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2018-99-114100

Published: 2018

Journal Articles

Decitabine Super-Responders: Challenging the Dogma of Long-Term Remission for Acute Myeloid Leukemia

Joseph Maakaron, MD, Gabriel N. Mannis, MD, Alison R. Walker, MD, Alice S. Mims, MD

Blood (2018) 132 (Supplement 1): 5190.

https://doi.org/10.1182/blood-2018-99-119916

Published: 2018

Journal Articles

Dying a fiery death: pyroptosis in MDS

Alison R. Walker

Blood (2016) 128 (25): 2875–2877.

https://doi.org/10.1182/blood-2016-10-746719

Published: 2016

Journal Articles

A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Bhavana Bhatnagar, DO, Rebecca B. Klisovic, MD, Alison R. Walker, MD MPH, Sumithra Vasu, MBBS, Alice S. Mims, MD MSCR, Katherine J. Walsh, MD, Gregory K. Behbehani, MD PhD, James S. Blachly, MD, Molly Vittorio, Qiuhong Zhao, Amy S. Ruppert, MAS, Shelley Orwick, BS, Parvathi Ranganathan, PhD, John C. Byrd, MD, William Blum, MD, Ramiro Garzon, MD

Blood (2016) 128 (22): 1651.

https://doi.org/10.1182/blood.V128.22.1651.1651

Published: 2016

Journal Articles

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Rajeswaran Mani, DVM PhD, Swagata Goswami, MS, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Tran, Xiaokui Mo, PhD MAS, Amber Gordon, MLS, Donna Bucci, David Lucas, PhD, Christopher L. Brooks, PhD, Alison R. Walker, MD MPH, William Blum, MD, John C. Byrd, MD, Gerard Lozanski, MD, Sumithra Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 580.

https://doi.org/10.1182/blood.V128.22.580.580

Published: 2016

Journal Articles

Performance of Quick Sepsis-Related Organ Failure Assessment (qSOFA) in Predicting Adverse Outcomes in Acute Leukemia Patients Receiving Induction Chemotherapy

John Vaughn, MD, David Kline, PhD, Nathan Denlinger, DO, Leslie Andritsos, MD, Alison R. Walker, MD MPH

Blood (2016) 128 (22): 2413.

https://doi.org/10.1182/blood.V128.22.2413.2413

Published: 2016

Journal Articles

A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485

Alice S. Mims, MD MSCR, Rebecca B Klisovic, MD, Ramiro Garzon, MD, Alison R. Walker, MD MPH, Steven M. Devine, MD, Katherine J. Walsh, MD, Sumithira Vasu, MBBS, Susan P. Whitman, PhD, Guido Marcucci, MD, Nyla A. Heerema, PhD, Michael A. Caligiuri, MD, Clara D. Bloomfield, MD, John C. Byrd, MD, Richard Piekarz, PhD MD, Michael R. Grever, MD, William Blum, MD

Blood (2016) 128 (22): 900.

https://doi.org/10.1182/blood.V128.22.900.900

Published: 2016

Journal Articles

The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia

Nicole R. Grieselhuber, MD PhD, Shaneice R. Mitchell, BS, Shelley Orwick, BS, Bonnie K. Harrington, DVM, Virginia M. Goettl, DVM, PhD, Alison R. Walker, MD MPH, Bhavana Bhatnagar, DO, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Sumithra Vasu, MBBS, William Blum, MD, James S. Blachly, MD, David M. Lucas, PhD, Ramiro Garzon, MD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3941.

https://doi.org/10.1182/blood.V128.22.3941.3941

Published: 2016

NARROW

Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax: A Real-World Experience in Pharmacovigilance

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Improved Overall Survival Among Luspatercept Responders and Predictors of Response

Outcomes in Patients with Acute Myeloid Leukemia Treated with CLAG (cladribine, cytarabine, filgrastim) and/or Mitoxantrone with Venetoclax

Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) Is Associated with Better Overall Survival

Aplastic Anemia: Insight from a Single Center Experience

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Universally Alloreactive Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial

Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Decitabine Super-Responders: Challenging the Dogma of Long-Term Remission for Acute Myeloid Leukemia

Dying a fiery death: pyroptosis in MDS

A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Performance of Quick Sepsis-Related Organ Failure Assessment (qSOFA) in Predicting Adverse Outcomes in Acute Leukemia Patients Receiving Induction Chemotherapy

A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485

The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only